Allied-Bristol Life Sciences Launches iβeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway
- Cancer therapeutics known as Inhibitors of Beta-Catenin Responsive Transcription (iCRTs) provide an approach to potential therapy for a number of hard-to-treat cancers
BOSTON (March 16, 2016) - Allied-Bristol Life Sciences, LLC (ABLS), a biopharmaceutical enterprise jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), announced that it has launched a new subsidiary, iβeCa Therapeutics, to license proprietary compounds from NYU School of Medicine that target the Wnt signalling pathway. The Wnt pathway plays a key role in the development and progression of a number of cancers affecting large numbers of patients. iβeCa Therapeutics will focus on further discovery and development activities needed to identify candidates for human clinical testing.
Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
- Allied-Bristol Life Sciences (ABLS) has licensed a proprietary platform technology from Yale University, developed in the laboratory of Dr. David Spiegel.
- The proprietary platform, and associated lead molecules known as Antibody-Recruiting molecules (ARMs), provide a novel approach for the treatment of cancer.
BOSTON (August 27, 2015) - Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), announced that it has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer, a leading cause of cancer-related deaths among American men.
Allied-Bristol Life Sciences Licenses Intellectual Property from Harvard University
- Allied-Bristol Life Sciences (ABLS) has licensed intellectual property developed in Professor Malcolm Whitman’s laboratory at Harvard.
- The intellectual property includes lead molecules and a differentiated mechanism to develop drugs for treating chronic fibrotic and autoimmune diseases.
BOSTON (June 22, 2015) - Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned by Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), today announced that it has entered into a licensing agreement with Harvard University based on research and intellectual property developed in Professor Malcolm Whitman’s lab at the Harvard School of Dental Medicine.
London's Best Kept Secret
-Woodford Investment Management LLP, April 29, 2015
Woodford Investment Management writes on its blog about Allied Minds’ Capital Markets Day, which introduced to the wider investment community the Allied Minds model and five of its subsidiaries – including Allied-Bristol Life Sciences. CEO Satish Jindal was among senior subsidiary executives who presented at the event in London.
Woodford Investment Management writes:
“All five of these subsidiary presentations gave a very interesting insight into the exciting technologies being developed by Allied Minds and provided evidence of the company’s unique and disciplined approach to unearthing and nurturing its subsidiaries towards commercial success. As chief executive, Chris Silva, summarised, ‘We’re looking for disruptive technologies – you’ve only seen a smattering of them today. We have 22 subsidiaries in total and their momentum and diversification gives us tremendous confidence for an exciting future.’
Hear, hear! We share that confidence and excitement.”